Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...
Source: globenewswire.com
Coverage Against News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Coverage Against. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.